Please login to the form below

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

lung cancer (NSCLC). ... DS-8201 ADC would add to AZ’s portfolio of emerging cancer drugs, sitting alongside cancer immunotherapy Imfinzi (durvalumab), targeted therapy Tagrisso for lung cancer and PARP inhibitor Lynparza (olaparib) for

Latest news

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Earlier-stage trials are ongoing in other advanced solid tumours including melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). ... Lilly’s presence in cancer is led by lung cancer chemotherapy drug Alimta (pemetrexed), which
SMC approves Yescarta and Keytruda, rejects Perjeta

Lung cancer is the most common cause of death from cancer in both men and women in Scotland, with a survival rate of only 9.8% five years after diagnosis. ... In August, Keytruda was also made available as a first-line treatment for patients with
BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy. Bristol-Myers Squibb isn’t giving up on its aspiration for Opdivo in first-line non-small cell lung cancer (NSCLC), a category ... It’s hoping to convince oncologists that a double cancer
Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ has suffered from numerous setbacks with Imfinzi – although it did score an encouraging approval in early-stage lung cancer last year which has helped to build momentum. ... However, the drug also failed to hit the first of two primary endpoints in
Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer. Researchers at the University of Amsterdam tested a diagnostic device developed by Dutch company Breathomix, and found that it was able to ... It is currently being studied in more than 1,

More from news
Approximately 101 fully matching, plus 760 partially matching documents found.

Latest Intelligence

A snapshot of Crescendo Biologics

What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... This molecule is designed for the treatment of prostate and other PSMA-positive tumours, such as
Leading AstraZeneca’s return to growth in Europe

Two leading examples of this are Tagrisso, which is now the leader in EGFR+ lung cancer treatment, and Lynparza, which targets BRCA and other mutations in multiple tumour types and is ... the only PARP inhibitor with positive phase 3 results in four
Encouraging signs in biomarker R&D

In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial
AI is transforming pharma R&D – now it can transform pharma marketing

In May 2019, Google reported that its AI could detect early signs of lung cancer in CT scans, in some cases identifying cancers missed by trained oncologists. ... A successful colonoscopy may prevent a cancer being missed, so Ava might help save lives!
2019: CRISPR and therapeutic gene editing comes of age

Back in 2016, Chinese scientists led by oncologist Lu You at Sichuan University in Chengdu, injected CRISPR-modified cells into a patient with a form of lung cancer at the West ... hope was that - without the brake of PD-1 – the edited cells would

More from intelligence
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest appointments

Astellas bolsters oncology clinical development leadership

breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
Iris Pauporté joins OSE Immunotherapeutics

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
Merck appoints ex-Pfizer exec as global head of oncology

lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
Merck appoints new senior vice president

Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

Hanson Zandi captures MPs support for The Times Clean Air Campaign

As a result, it is estimated the approximately 66, 000 people die prematurely every year of conditions such as lung cancer and asthma, with children being especially vulnerable.
Artificial Intelligence in Healthcare

trust the same digital system to recommend their treatment pathway for a potentially lethal cancer. ... Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer

5]. In spite of these statistics, funding for pancreatic cancer and disease awareness are low. ... Misconception. Reality. Pancreatic cancer is rare [8]. Although the incidence of pancreatic cancer is lower than other common cancers like breast, bowel
How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led by established 1st generation tyrosine kinase inhibitors (TKIs). There were
Therapy Watch expands oncology and IBD portfolios

US. CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. ... Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's